Daily Market BriefHealthcare

Dupilumab Hits $11.9B; Amgen Blocks State Price Cap

Big Pharma advances on blockbuster sales and regulatory wins while Pfizer signals M&A intent and Thermo Fisher backs cystic fibrosis trial.

Money365.Market AI
3 min read
Market MoodRisk-On
Sentiment+68Bullish

Key DriverStrong blockbuster drug performance and favorable regulatory developments support sector gains

Today in 30 Seconds

  • Dupilumab reached $11.9B in global sales driven by COPD expansion
  • Amgen gained 3.1% after favorable court ruling on Enbrel pricing
  • Thermo Fisher partners on Phase III cystic fibrosis trial

Top Movers

$AMGN▲ +3.1%

Amgen

Court blocks state price cap on Enbrel

All Briefs

Healthcare Market Overview

Bullish

NYSE Healthcare Index

+2%+2%
$JNJ$UNH

Healthcare stocks advanced with the NYSE Healthcare Index rising 2% as the sector benefited from strong commercial performance of blockbuster drugs and favorable regulatory developments. Members of Congress have been adding positions in Johnson & Johnson ($JNJ) and UnitedHealth ($UNH), signaling confidence in healthcare policy and regulatory frameworks. The sector showed resilience amid broader market uncertainty, with S&P 500 futures edging down 0.01% on cooling labor market data.

Big Pharma & Biotech

Bullish

Dupilumab Global Sales

$11.9B

Amgen Stock

+3.1%+3.1%

Antidiabetic Market 2026

$115.02B

Antidiabetic Market 2035

$309.84B+11.62% CAGR
$REGN$AMGN$PFE$MRK

Regeneron Pharmaceuticals ($REGN) continued to drive commercial success with Dupilumab achieving record sales of $11.9 billion globally, propelled by its established market presence, new indications including COPD, and strong clinical performance across multiple conditions. Amgen ($AMGN) shares jumped 3.1% after receiving a favorable court ruling that blocked a first-of-its-kind state price cap on its blockbuster drug Enbrel, providing relief on pricing pressure concerns. Pfizer ($PFE) signaled acquisition intent with its CEO highlighting the company's balance sheet capacity for deals, while Merck ($MRK) hit new highs and traded in a buy zone. The global antidiabetic drugs market is projected to reach $309.84 billion by 2035, expanding at an 11.62% CAGR from $115.02 billion expected in 2026, according to Healthcare Foresights research.

Clinical Trials & Manufacturing

Neutral

Yutrepia Q1 Sales

$130M
$TMO

Thermo Fisher Scientific ($TMO) announced a partnership with Arcturus to support the Phase III ARCT-032 cystic fibrosis trial, providing integrated manufacturing, clinical research and commercial readiness services. The collaboration positions Thermo Fisher to support advanced gene therapy development through late-stage clinical testing. LQDA's Yutrepia launch continued gaining traction with $130 million in Q1 sales, with rising prescriptions and profitability as the company expands in pulmonary arterial hypertension.

Health Insurance & Managed Care

Neutral

Cigna Pharmacy Forward Investment

$100M
$UNH

UnitedHealth ($UNH) attracted congressional investment interest as lawmakers positioned in health insurance providers following the Q1 earnings season. Cigna's Evernorth launched AI-powered Pharmacy Forward with a $100M investment to accelerate specialty prescriptions, reduce delays and improve efficiency in specialty pharmacy operations. The health insurance providers sector completed Q1 reporting with performance varying across the industry.

Medical Devices & Diagnostics

Neutral

Boston Scientific Neuromodulation Growth

+15%+15%
$ISRG$ABT$ABBV

Intuitive Surgical ($ISRG) appeared in investor discussions around market capitalization and long-term compounding opportunities in the surgical robotics sector. Abbott Laboratories ($ABT) was referenced in analysis of Boston Scientific's portfolio, which showed acceleration in core franchises including Neuromodulation and Interventional Oncology businesses posting organic sales growth of 15% last quarter. AbbVie ($ABBV) was highlighted in research reports examining the broader healthcare sector's performance and opportunities.

Looking Ahead

Neutral
$AMGN$PFE$MRNA

The sector faces continued scrutiny over drug pricing policy as Amgen's court victory on state price caps sets a precedent for industry pricing dynamics. Pfizer's M&A signaling suggests potential consolidation activity ahead as the company seeks to deploy its balance sheet. Moderna ($MRNA) appeared in analysis of cash-heavy stocks with warning signs, as companies with strong balance sheets face questions about growth generation and profitability consistency. Medicare negotiations and regulatory frameworks remain key watchpoints for policy-sensitive healthcare names.

Risk Flags

WatchDrug pricing litigation and state-level price cap initiatives create regulatory uncertainty
NoteCash-heavy biotech firms face questions on capital deployment and growth trajectory

Important Disclaimer — Not Investment Advice

Disclaimer: This article is provided by Money365.Market for general information and educational purposes only. It is not financial advice, a personal recommendation, or an inducement to buy, sell, or invest in any security or product. Capital is at risk and the value of investments can go down as well as up; past performance does not indicate future results. You should seek independent advice from an FCA-authorised adviser before making any financial decision.

Nothing here is an offer or a solicitation to buy or sell anything, and reading it creates no advisory or fiduciary relationship between you and Money365.Market. Any decision you take is your own.

  • You can lose money — including all of it. Individual companies can and do fail, and some of the assets discussed can fall to zero. Only commit money you can afford to lose, and never borrow to invest on the strength of anything you read here.
  • Forecasts are opinion, not fact. Any valuation model, scenario, fair-value range, estimate or other forward-looking statement is illustrative, rests on assumptions that may prove wrong, and is never a price target, a forecast of actual outcomes, or a promise of any return.
  • Published at a point in time. Figures were believed accurate on the publication or last-updated date shown above and are not maintained afterwards; we are under no obligation to update them. Market and company data comes from third-party sources and is provided without warranty of accuracy, completeness or timeliness.
  • Automated content. This brief was compiled by an automated pipeline from validated news and market-data sources and passed through editorial and compliance checks. Automated content can still contain errors — verify anything you intend to rely on.
  • We are not regulated. Money365.Market is not authorised or regulated by the UK Financial Conduct Authority, is not registered with the U.S. Securities and Exchange Commission or FINRA as an investment adviser or broker-dealer, and is not a tax adviser. We hold no licence to give personal financial advice and do not do so.
  • Interests and independence. Money365.Market is not affiliated with, endorsed by or sponsored by any company, fund, exchange or platform mentioned, and is not paid to feature them. The author may hold positions in securities or assets discussed. The site earns revenue from advertising, subscriptions and, where labelled, affiliate links; this does not influence what we publish.
  • Your jurisdiction matters. Tax treatment, contribution limits, product availability and investor protections differ by country and can change. Speak to a qualified tax professional for tax matters, and to a locally licensed adviser if you are outside the UK.

Full terms: Disclaimer · Terms of Service · Privacy Policy

Back to All Briefs